

■ Toledo cells

Human Toledo cells were isolated from the peripheral blood of a patient with non-hogkin's DLBC lymphoma.

■ Tumour growth *in vivo*

The cells were collected from a tissue culture flask and injected subcutaneously in the right flank of SCID-CB17 mice. The resulting tumours were monitored by measuring two diameters with calipers, and extrapolating the volume to a sphere.

The mice bearing Toledo tumours can be treated by intra-peritoneal, intra-venous, intra-tumoral or subcutaneous injection of the compounds. Per os administration is also possible.




Figure 1: Tumour growth curve of the Toledo cells as xenograft
Mean \pm SEM (n=3; take rate 100%)

Antineo can also perform an intra-medullar implantation.

■ Standard-Of-Care Drug Reponses

rituximab 30 mg/kg qw \rightarrow Response




Figure 2: Effect of rituximab treatment on Toledo tumour growth
Mean \pm SEM (n=3 per group; take rate 100%)

A Toledo resistant to rituximab model, developed *in vivo* without genetic modifications, are available at Antineo (model ID Toledo rituxR).